Benralizumab Proves Noninferior to Mepolizumab for EGPA
SAN DIEGO — Treatment with benralizumab (Fasenra) achieved remission at 36 and 48 weeks at rates similar to those of mepolizumab ...
SAN DIEGO — Treatment with benralizumab (Fasenra) achieved remission at 36 and 48 weeks at rates similar to those of mepolizumab ...
Editor's note: Find the latest long COVID news and guidance in Medscape's Long COVID Resource Center. How have you been sleeping? ...
A pair of new studies published this week about long COVID have shed more light on the sometimes-disabling condition that ...
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. TOPLINE: Despite COVID-19 triggering autoimmune conditions ...
Hospitalizations for COVID-19 in the United States have increased for 8 weeks in a row. Data from Florida and Georgia ...
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. A new meta-analysis has shown that ...
TOPLINE: The indirect and direct costs of alcohol-associated liver disease (ALD) could sap the US economy of $880 billion from ...
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. COVID-19 metrics keep ticking up, as ...
Today, in Nature, a groundbreaking and compelling report on the genomics of why some people do not manifest symptoms of ...
MILAN, Italy — Rheumatic disease is not considered a significant risk factor for long COVID, according to the findings of ...
© Pharma News Hubb All rights reserved.
Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.
© 2022 Pharma News Hubb All rights reserved.